1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material: Kurvelo™
Levonorgestrel and Ethinyl Estradiol Tablets USP
0.15 mg/0.03 mg

Manufacturer: Lupin Limited
Pithampur (M.P.) - 454 775
INDIA

Distributor: Lupin Pharmaceuticals, Inc.
Harborplace Tower, 21st Floor
111, South Calvert Street
Baltimore, MD 21202
United States
Tel. 001-410-576-2000
Fax. 001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients
CAS
Levonorgestrel 797-63-7
Ethinyl Estradiol 57-63-6

3. HAZARD IDENTIFICATION

Fire and Explosion
Expected to be non-combustible.

Health
Oral contraceptives should not be used in women with any of the following conditions: Thrombophlebitis or thromboembolic disorders.

- A past history of deep-vein thrombophlebitis or thromboembolic disorders.
- Cerebral-vascular or coronary-artery disease.
- Known or suspected carcinoma of the breast.
- Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia.
- Undiagnosed abnormal genital bleeding.
- Cholestatic jaundice of pregnancy or jaundice with prior pill use.
4. FIRST AID MEASURE

Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact
Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment
Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc.

OVERDOSAGE
Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.

5. FIRE FIGHTING MEASURE

Fire and Explosion Hazards
Assume that this product is capable of sustaining combustion.

Extinguishing Media
Water spray, carbon dioxide, dry chemical powder or appropriate foam.
6. ACCIDENTAL RELEASE MEASURES

Personal Precautions
Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods
Collect and place it in a suitable, properly labeled container for recovery or disposal.

7. HANDLING AND STORAGE

Handling
No special control measures required for the normal handling of this product.

Storage
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical Form
Kurvelo Tablets (levonorgestrel and ethinyl estradiol tablets USP) (3 x 28) are available in packages of 3 wallets, each containing 28 tablets as follows:
Each blister strip contains 21 light orange tablets of 0.15 mg Levonorgestrel and 0.03 mg Ethinyl Estradiol, debossed with “LU” on one side and “U31” on the other side.

7 inert pink round biconvex tablets debossed with “LU” on one side and “U32” on the other side.

They are supplied as follows:

Kurvelo tablets are available in a wallet (NDC 68180-844-11) containing 28 tablets, such 3 wallets are packed in a carton (NDC 68180-844-13).

10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Carcinogenesis

Numerous epidemiological studies have been performed on the incidence of breast, endometrial, ovarian and cervical cancer in women using oral contraceptives. Although the risk of having breast cancer diagnosed may be slightly increased among current and recent users of combined oral contraceptives (RR=1.24), this excess risk decreases over time after combination oral contraceptive discontinuation and by 10 years after cessation the increased risk disappears. The risk does not increase with duration of use and no consistent relationships have been found with dose or type of steroid. The patterns of risk are also similar regardless of a woman's reproductive history or her family breast cancer history. The subgroup for whom risk has been found to be significantly elevated is women who first used oral contraceptives before age 20, but because breast cancer is so rare at these young ages, the number of cases attributable to this early oral contraceptive use is extremely small. Breast cancers diagnosed in current or previous oral contraceptive users tend to be less clinically advanced than in never-users. Women who currently have or have had breast cancer should not use oral contraceptives because breast cancer is a hormone sensitive tumor.

Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia or invasive cervical cancer in some populations of women. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. In spite of many studies of the relationship between oral contraceptive use and breast cancer and cervical cancers, a cause-and-effect relationship has not been established.
12. ECOLOGICAL INFORMATION

No relevant studies identified.

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

14. TRANSPORT INFORMATION

**IATA/ICAO - Not Regulated**
- IATA Proper shipping Name : N/A
- IATA UN/ID No : N/A
- IATA Hazard Class : N/A
- IATA Packaging Group : N/A
- IATA Label : N/A

**IMDG - Not Regulated**
- IMDG Proper shipping Name : N/A
- IMDG UN/ID No : N/A
- IMDG Hazard Class : N/A
- IMDG Flash Point : N/A
- IMDG Label : N/A

**DOT - Not Regulated**
- DOT Proper shipping Name : N/A
- DOT UN/ID No : N/A
- DOT Hazard Class : N/A
- DOT Flash Point : N/A
- DOT Packing Group : N/A
- DOT Label : N/A

15. REGULATORY INFORMATION

This Section Contains Information relevant to compliance with other Federal and/or state laws.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.
**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.